← board
PULM
distress 5/10 · elevated risk$1.69+0%today-74% from 52w high
Revenue
pre-revenue
Liquidity
$3M
Runway
0.3 yrs
Shares 1y
0%
Price & events
-36.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
+5.2%
1W
+12.9%
1M
+21.0%
3M
-36.3%
6M
-71.9%
1Y
-14.0%
2Y
-90.5%
5Y
-93.3%
All
Overview
- Market Cap
- $6.19M
- Volume
- 834
- 52 Week Range
- $1.19 – $6.55
- Total Shares
- 3.65M
- Float Shares
- 3.65M
- Short %
- 2.52%
- % Held by Insiders
- 0.77%
- % Held by Institutions
- 9.02%
- RVOL
- 0.01x
- Beta
- 1.90
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026-04-16partnershipClosed private placement of Series B Preferred Stock with affiliate of Eos SENOLYTIX, as part of planned merger.SEC 8-K
- 2026-02-28withdrawalCullgen terminated the Agreement and Plan of Merger with Pulmatrix.SEC 8-K
- 2025-12-17partnershipPulmatrix and Cullgen mutually waived the no-solicitation clause to explore alternative transactions while continuing to pursue merger approval from CSRC.SEC 8-K
- 2025-06-16partnershipStockholders approved merger with CullgenSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.